The VDL is currently restructuring and not providing services at this time. For all request of viral vectors, please visit the Gene Vector Core Website or send an email to genevector@bcm.edu. Since ...
Vector Science & Therapeutics (TSXV: PAIN) ("Vector" or the "Company") today announced that it has entered into a development and manufacturing agreement with MPP Group LLC ("MPP"), a Mequon, ...
TUSTIN, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient ...
Recombinant adeno-associated virus (rAAV) is a leading viral vector modality for gene therapy, with several approved treatments and hundreds of ongoing clinical trials. rAAV manufacturing, while ...
All vectors produced by the VDL are manufactured in compliance with Good Laboratory Practices. Our commitment to GLP regulations makes all of our vectors suitable to pre-clinical studies. There are ...
The global viral vector development market size is poised for remarkable growth, with a projected valuation of US$ 730.7 Million by the end of 2023 and an anticipated expansion at a Compound Annual ...
Kirkland-based Vector Development Co. recently announced plans to build a $9.5M, 78K SF distribution center in Tacoma. The facility will be leased to one or more distribution, warehouse or ...
Vector Development Co. plans to begin construction on MI-5 Business Park, industrial space at 4000 156th St. NE. The $32M facility will be leased to distribution and manufacturing tenants. It is being ...
The VDL is currently restructuring and not providing services at this time. For all request of viral vectors, please visit the Gene Vector Core Website or send an email to genevector@bcm.edu. Since ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results